Foghorn Therapeutics Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
FHTX$1.90-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’
Condensed Consolidated Statements of Stockholders’ Deficit
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Gain (Loss) · AccumulatedDeficit · TotalStockholders’Deficit | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balances at December 31, 2025 | 56,657,329 | $6 | $523,937 | $24 | $(632,467) | $(108,500) |
| Issuance of common stock from direct offering, net of offering costs | 2,030,314 | — | 10,213 | — | — | 10,213 |
| Issuance of pre-funded warrants from direct offering, net of offering costs | — | — | 27,271 | — | — | 27,271 |
| Issuance of series 1 warrants from direct offering, net of offering costs | — | — | 2,942 | — | — | 2,942 |
| Issuance of series 2 warrants from direct offering, net of offering costs | — | — | 9,226 | — | — | 9,226 |
| Issuance of common stock upon exercise of stock options and employee stock purchase plan | 22,847 | — | 89 | — | — | 89 |
| Stock-based compensation expense | — | — | 2,383 | — | — | 2,383 |
| Unrealized losses on marketable securities | — | — | — | (157) | — | (157) |
| Net loss | — | — | — | — | (19,875) | (19,875) |
| Balances at March 31, 2026 | 58,710,490 | 6 | 576,061 | (133) | (652,342) | (76,408) |
| Issuance of common stock upon exercise of stock options and employee stock purchase plan | 3,782 | — | 9 | — | — | 9 |
| Stock-based compensation expense | — | — | 2,550 | — | — | 2,550 |
| Unrealized losses on marketable securities | — | — | — | (1) | — | (1) |
| Net loss | — | — | — | — | (7,191) | (7,191) |
| Balances at June 30, 2026 | 58,714,272 | $6 | $578,620 | $(134) | $(659,533) | $(81,041) |
| Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Gain (Loss) · AccumulatedDeficit · TotalStockholders’Deficit | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balances at December 31, 2024 | 55,594,131 | $6 | $512,515 | $135 | $(558,184) | $(45,528) |
| Issuance of common stock upon exercise of stock options and employee stock purchase plan | 127,209 | — | 139 | — | — | 139 |
| Stock-based compensation expense | — | — | 2,692 | — | — | 2,692 |
| Unrealized losses on marketable securities | — | — | — | (121) | — | (121) |
| Net loss | — | — | — | — | (18,834) | (18,834) |
| Balances at March 31, 2025 | 55,721,340 | 6 | 515,346 | 14 | (577,018) | (61,652) |
| Issuance of common stock upon exercise of stock options and employee stock purchase plan | 81,855 | — | 254 | — | — | 254 |
| Stock-based compensation expense | — | — | 2,733 | — | — | 2,733 |
| Unrealized losses on marketable securities | — | — | — | (58) | — | (58) |
| Net loss | — | — | — | — | (17,936) | (17,936) |
| Balances at June 30, 2025 | 55,803,195 | $6 | $518,333 | $(44) | $(594,954) | $(76,659) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.